Nature sub-journal: Screening of clinical drug candidates through organoids derived from solid tumor cancer patients
Time of Update: 2022-08-12
. On April 25, 2022, researchers from CrownBio, Merus, and the Barcelona Institute of Science and Technology jointly published a paper entitled: Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR in Nature Cancer, a sub-journal of Nature × Research paper on LGR5 bispecific antibody with efficacy in epithelial tumors .
【Chinese Achievements】Professor Shen Lin from Beijing Cancer Hospital leads the International Research on Esophageal Cancer Weekly Report on Tumor Treatment
Time of Update: 2022-06-04
NEJM: Results from the AGILE trial confirm significant improvement in ivonib plus azacitidine compared with placebo plus azacitidine in patients with newly diagnosed IDH1-mutant acute myeloid leukemia who are ineligible for induction chemotherapy Event-free survival, remission and overall survival .
Brit J Cancer: Microbial markers for predicting colorectal tumor risk
Time of Update: 2022-04-22
DigestionThus, this review provides evidence supporting the association between different types of microbial species and their perspective on their predictive value for colorectal tumors .
This review provides evidence supporting the association between different types of microbial species and their predictive value for colorectal tumors .
Eur Heart J: Incidence, risk factors and death of atrial fibrillation in breast cancer patients
Time of Update: 2021-12-03
Recently, the heart blood vessels magazine field authority Eur Heart published a research article on J, the purpose of this study was to evaluate breast cancer patients nationwide AF incidence, risk factors and related mortality .
Laboratory studies have shown that commonly used diabetes drugs are expected to treat rare childhood brain tumors
Time of Update: 2021-10-22
An international research team led by the University of Michigan Health Rogel Cancer Center published a report in "Science translmedicine" that in laboratory research, a type of The diabetes drug metformin is expected to treat a rare brain tumor in children .
Professor Shen Lin: Precise treatment is ready to take off, a grand gathering of gastrointestinal tumors
Time of Update: 2021-08-08
New drug research and development has promoted the precise development of gastrointestinal tumors | Professor Lin Shen: Precise targeted therapy for colorectal cancer is bound to be its future development direction .
Dig Dis Sci: Patients with early-onset colorectal cancer are at increased risk of developing second primary malignancies
Time of Update: 2021-06-01
Figure: The risk of second primary tumors in different locations This study shows that the lifetime risk of SPM for people with eoCRC is nearly 50% higher than that of the general population.
Screening for colorectal cancer, the 2020 China Guidelines recommend
Time of Update: 2021-05-09
(Strong recommendation, GRADE evidence grade: high) 4 Starting and ending age for general population screening ➤ It is recommended that the general population begin to receive colorectal cancer risk assessment from 40 years old (Weak recommendation, GRADE evidence grade: low).
New lysovirus therapy: intravenously break through the limits of the route of drugation
Time of Update: 2021-02-24
OncoMyx Therapeutics presented preclinical efficacy data for a multigene lysovirus therapy it developed at the 2020 Cancer Immunotherapy Association (SITC 2020) meeting: it was shown for the first time that the therapy significantly slowed the growth of multiple tumor types when administered intravenously or intracoma alone or in combination with immunosuppressants, and reduced tumor and prolonged animal life when used in combination with immunosuppressants.
The EOC202 overseas trial significantly improved the total survival of patients with advanced breast cancer
Time of Update: 2021-01-06
, similar to AIPAC, clinical studies in China will continue to focus on HER2-negative/HR-positive metastatic breast cancer patients who are suitable for chemotherapy after progression in endocrine therapy, while refining the treatment population to maximize potential research benefits.
Br J Cancer: CDX2 regulates the expression of Snail and the stability β-catenin to inhibit the invasion and metastasis of colorectal cancer
Time of Update: 2020-12-16
Previous studies have shown that CDX2 is involved in the development of various cancers and plays a vital role in the invasion and metastasis of cancer, but the role of CDX2 in the CRC endosthast-interstital transformation (EMT) process is still unknown.
Yassin Pharmaceutical Apoptosis Inhibitors were certified by 2 more FDA orphan drugs
Time of Update: 2020-10-24
Asasin Pharmaceutical Apoptosis Inhibitors Received 2 more FDA Orphan Drug Certified Pharmaceutical Rubik's Cubes Source: Pharmaceutical Rubik's Cube 10-09 Until October 9, Asasin Pharmaceuticals announced that the FDA has awarded its MDM2-p53 inhibitors APG-115, Bcl-2/Bcl-xL inhibitor APG-1252 are two orphan drug qualifications for the treatment of acute myeloid leukemia (AML) and small cell lung cancer (SCLC).
JAMA: Early returns since the era of precision medicine
Time of Update: 2020-08-21
2018, a study published in JAMA Oncology magazine reported that as of January 2018, only 8 percent of cancer patients would be able to use precision drugs, while in fact only 5 percent would end up benefiting.
Phase III study of hpatinib in the treatment of advanced gastric cancer
Time of Update: 2020-04-03
According to Hengrui pharmaceutical company, apatinib's phase III research on the treatment of advanced gastric cancer will make an oral report at the annual meeting of the American Society of Clinica
PNAs: computer technology helps to reveal the molecular mechanism of cancer deterioration
Time of Update: 2020-02-19
February 19, 2020 / BIOON / -- recently, a study led by children's Hospital of Philadelphia (CHOP) revealed the relationship between variable protein cleavage and oncogene The results were published i